Home > Journals > Minerva Oftalmologica > Past Issues > Minerva Oftalmologica 2003 September-December;45(3-4) > Minerva Oftalmologica 2003 September-December;45(3-4):47-56

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Oftalmologica 2003 September-December;45(3-4):47-56

Copyright © 2003 EDIZIONI MINERVA MEDICA

language: Italian

Glaucoma therapy: the cannabinoids way

Rossi S., Rinaldi M., Romano M., Rinaldi B., D’Amico M., Di Filippo C.


PDF


The newly discovered cannabinoids and their endogenous ligand arachidonylethanolamide opened the way to the use of the cannabinoids in medicine, particularly in the glaucoma therapy. Actually, the focus is posed on drugs predominately acting on specific CB1 receptors. These drugs seem to be able to reduce the 1st symp-tom of glaucoma, the ocular hypertension. New technologies such as microemulsion and cyclodextrins based pharmaceutical preparations enable these drugs to topical ophthalmic administration. This would minimize drug concentration in the systemic circulation and possible consequent adverse-side effects (hypotension, tachycardia and psychic disorders).

top of page